Compare · ASND vs HOOK
ASND vs HOOK
Side-by-side comparison of Ascendis Pharma A/S (ASND) and HOOKIPA Pharma Inc. (HOOK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ASND and HOOK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ASND is the larger of the two at $13.65B, about 332.6x HOOK ($41.0M).
- Over the past year, ASND is up 34.2% and HOOK is down 8.4% - ASND leads by 42.6 points.
- ASND has hit the wire 12 times in the past 4 weeks while HOOK has been quiet.
- ASND has more recent analyst coverage (25 ratings vs 11 for HOOK).
- Company
- Ascendis Pharma A/S
- HOOKIPA Pharma Inc.
- Price
- $228.56+3.76%
- $0.87-3.61%
- Market cap
- $13.65B
- $41.0M
- 1M return
- -0.04%
- +0.00%
- 1Y return
- +34.16%
- -8.41%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2019
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 11
Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Latest ASND
- SEC Form 6-K filed by Ascendis Pharma A/S
- Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
- SEC Form 6-K filed by Ascendis Pharma A/S
- Amendment: SEC Form 8-A12B/A filed by Ascendis Pharma A/S
- SEC Form 6-K filed by Ascendis Pharma A/S
- Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
- SEC Form 6-K filed by Ascendis Pharma A/S
- SEC Form 6-K filed by Ascendis Pharma A/S
- Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
- New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia
Latest HOOK
- HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics
- HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
- HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
- Chief Executive Officer Peters Malte sold $20,684 worth of shares (25,172 units at $0.82), decreasing direct ownership by 32% to 54,347 units (SEC Form 4)
- SEC Form 15-12G filed by HOOKIPA Pharma Inc.
- SEC Form EFFECT filed by HOOKIPA Pharma Inc.
- SEC Form EFFECT filed by HOOKIPA Pharma Inc.
- SEC Form 25 filed by HOOKIPA Pharma Inc.
- SEC Form S-8 POS filed by HOOKIPA Pharma Inc.
- SEC Form S-8 POS filed by HOOKIPA Pharma Inc.